Analytical Data
-
Gene name
SLC16A4
- Application
-
Alternative Names
Monocarboxylate transporter 4 Solute carrier family 16 member 4
-
Species
Human
-
Source
E. coli
-
Tag
N- His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
O15374
-
Expression Region
196–299aa
-
Molecular Weight
17.7 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
SLC16A4, also known as the Sodium-Coupled Monocarboxylate Transporter 4 (MCT4), plays a crucial role in the transport of lactate and other monocarboxylates across cellular membranes, facilitating energy metabolism and maintaining pH balance in tissues such as muscle and brain. The importance of SLC16A4 in cellular processes has garnered significant interest, particularly in the context of various physiological and pathological conditions, including exercise physiology, cancer, and neurodegenerative diseases. Research has shown that altered expression of SLC16A4 can affect lactate clearance and overall metabolic homeostasis, implicating it in the development of metabolic disorders. Additionally, SLC16A4's involvement in the export of lactate during glycolytic activity in tumors makes it a potential therapeutic target for cancer treatments aimed at reprogramming tumor metabolism. The generation of recombinant SLC16A4 protein has become essential for understanding its structure-function relationships, developing pharmacological agents, and exploring therapeutic interventions. By studying this protein in vitro and in vivo, researchers aim to unravel its mechanisms of action and determine its role in various biological contexts, potentially leading to novel strategies for managing diseases associated with disrupted metabolic pathways. The advent of advanced protein engineering techniques, such as CRISPR and protein crystallography, has further enhanced our ability to investigate SLC16A4 at a molecular level, paving the way for impactful discoveries in the field of metabolic research.
